Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population

Infection, Genetics and Evolution

Volumn 11, Issue 7, 2011, Pages 1682-1689

  Cui, Qian ^a   Zhang, Yong Xiang ^b   Su, Jing ^a   Chen, Xin ^a   Ding, Keqin ^a   Lei, Na ^a   Liu, Yan ^a   Li, Jun ^b   Zhang, Yun ^c   Yu, Rong Bin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Medical Institute of Nanjing Army   (China)

Author keywords

Hepatitis C virus (HCV); IFNAR2; IL10RB; IL28RA; Outcome; Polymorphism

Indexed keywords

GENOMIC DNA;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; IFNAR2 GENE; IL10RB GENE; IL28RA GENE; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; VIRAL GENETICS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CASE-CONTROL STUDIES; CHINA; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-10 RECEPTOR BETA SUBUNIT; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, CYTOKINE; RISK FACTORS; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 80053563904     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.06.016     Document Type: Article

References (32)

1. Ank N., West H., Bartholdy C., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006, 80:4501-4509.
2. Askar E., Ramadori G., Mihm S. Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. J. Med. Virol. 2010, 82:1859-1868.
3. Bao Y.P., Liu Z.M. Systematic review of HIV and HCV infection among drug users in China. Int. J. STD AIDS 2009, 20:399-405.
4. Bhattacherjee V., Prescott L.E., Pike I., Rodgers B., Bell H., El-Zayadi A.R., Kew M.C., Conradie J., Lin C.K., Marsden H. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5, and 6. J. Gen. Virol. 1995, 76:1737-1748.
5. Bialek S.R., Terrault N.A. The changing epidemiology and natural history of hepatitis C virus infection. Clin. Liver Dis. 2006, 10:697-715.
6. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., Stark G.R. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 2007, 6:975-990.
7. Chae S.C., Park Y.R., Li C.S., Lee J.H., Yang Y.S., Zhang Q., Kim K.S., Chung H.T. Analysis of the variations in IL-28RA gene and their association with allergic rhinitis. Exp. Mol. Med. 2006, 38:302-309.
8. Chen J.Y., Lin C.Y., Wang C.M., Lin Y.T., Kuo S.N., Shiu C.F., Chang S.W., Wu J., Sheen I.S. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011, 12:300-309.
9. Sero-epidemiological study of viral hepatitis in China 1997, 60-71. Scientific and Technical Documents Publishing House, Beijing. Z.C. Dai, G.M. Qi (Eds.).
10. Dellgren C., Gad H.H., Hamming O.J., Melchjorsen J., Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 2009, 10:125-131.
11. Fortunato G., Calcagno G., Bresciamorra V., Salvatore E., Filla A., Capone S., Liguori R., Borelli S., Gentile I., Borrelli F., Borgia G., Sacchetti L. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J. Interferon Cytokine Res. 2008, 28:141-152.
12. Frodsham A.J., Zhang L., Dumpis U., Taib N.A., Best S., Durham A., Hennig B.J., Hellier S., Knapp S., Wright M., Chiaramonte M., Bell J.I., Graves M., Whittle H.C., Thomas H.C., Thursz M.R., Hill A.V. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl. Acad. Sci. USA 2006, 103:9148-9153.
13. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
14. Gong Q.M., Kong X.F., Yang Z.T., Xu J., Wang L., Li X.H., Jin G.D., Gao J., Zhang D.H., Jiang J.H., Lu Z.M., Zhang X.X. Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. J. Viral Hepat. 2009, 16:674-680.
15. Jordan W.J., Eskdale J., Srinivas S., Pekarek V., Kelner D., Rodia M., Gallagher G. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 2007, 8:254-261.
16. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69-77.
17. Li M., Liu X., Zhou Y., Su S.B. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 2009, 86:23-32.
18. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J. Hepatol. 1999, 3:9-16.
19. Müller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
20. Pagliaccetti N.E., Eduardo R., Kleinstein S.H., Mu X.J., Bandi P., Robek M.D. Interleukin-29 Functions Cooperatively with Interferon to Induce Antiviral Gene Expression and Inhibit Hepatitis C Virus Replication. J. Biol. Chem. 2008, 283:30079-30089.
21. Post J., Ratnarajah S., Lloyd A.R. Immunological determinants of the outcomes from primary hepatitis C infection. Cell. Mol. Life Sci. 2009, 66:733-756.
22. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 2008, 8:559-568.
23. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14:778-809.
24. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
25. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., Klucher K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
26. Simmonds P., McOmish F., Yap P.L., Chan S.W., Lin C.K., Dusheiko G., Saeed A.A., Holmes E.C. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of new virus type and restriction on sequence diversity. J. Gen. Virol. 1993, 74:661-668.
27. Stephens M., Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 2003, 73:1162-1169.
28. Sun J., Yu R., Zhu B., Wu J., Larsen S., Zhao W. Hepatitis C infection and related factors in hemodialysis patients in china: systematic review and meta-analysis. Ren. Fail. 2009, 31:610-620.
29. Taniuchi S., Masuda M., Teraguchi M., Ikemoto Y., Komiyama Y., Takahashi H., Kino M., Kobayashi Y. Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. J. Clin. Immunol. 2005, 25:309-313.
30. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
31. Welzel T.M., Morgan T.R., Bonkovsky H.L., Naishadham D., Pfeiffer R.M., Wright E.C., Hutchinson A.A., Crenshaw A.T., Bashirova A., Carrington M., Dotrang M., Sterling R.K., Lindsay K.L., Fontana R.J., Lee W.M., Di Bisceglie A.M., Ghany M.G., Gretch D.R., Chanock S.J., Chung R.T., O'Brien T.R. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009, 49:1847-1858.
32. Wietzke-Braun P., Maouzi A.B., Mänhardt L.B., Bickeböller H., Ramadori G., Mihm S. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol. 2006, 18:991-997.